Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 53

Sort by

Sort Order Select

Journal Articles

Novel PD-L1 Blocking Peptide with Mitochondrial Targeting Sequence: A Strategy to Counteract Resistance in T-Cell Immunotherapy for Myeloma

Smriti Gurung, Colin Crean, David Lloyd Halladay, Judith L. Anderson, Rafat Abonour, Brian A. Walker, Kelvin P. Lee, John Mitchell Chirgwin, Attaya Suvannasankha

Blood (2024) 144 (Supplement 1): 6861.

https://doi.org/10.1182/blood-2024-211787

Published: 2024

Journal Articles

Safety and Efficacy of Teclistamab in a Patient Series with Relapsed/Refractory Multiple Myeloma and Severe Renal Impairment on Dialysis

Nutdanai Roila, Attaya Suvannasankha, Rafat Abonour

Blood (2024) 144 (Supplement 1): 6912.

https://doi.org/10.1182/blood-2024-201209

Published: 2024

Journal Articles

A Timelapse Assessment of Education on Heavily Pretreated Multiple Myeloma: Clinician Perceptions and Patient Experiences

Tariqa Ackbarali, Beth M. Faiman, Attaya Suvannasankha, Melissa Alsina, Monique A. Hartley-Brown, Hans C. Lee

Blood (2024) 144 (Supplement 1): 7964.

https://doi.org/10.1182/blood-2024-212026

Published: 2024

Journal Articles

Linvoseltamab in Patients with Relapsed/Refractory Multiple Myeloma: Longer Follow-up and Selected High-Risk Subgroup Analyses of the Linker-MM1 Study

Blood (2024) 144 (Supplement 1): 3369.

https://doi.org/10.1182/blood-2024-199733

Published: 2024

Journal Articles

Characterization of Anthropometric Changes in Patients with Relapsed/Refractory Myeloma Treated with BCMA Bispecific Antibody Teclistamab

Setarah Mohammad Nader, S. Tyler Jines, Christopher Collier, Teresa Zimmers, Rafat Abonour, Sherif Farag, Mohammad Abu Zaid, Kelvin P. Lee, Attaya Suvannasankha

Blood (2023) 142 (Supplement 1): 6683.

https://doi.org/10.1182/blood-2023-182754

Published: 2023

Journal Articles

Health-Related Quality of Life (HRQoL) Among Patients with Triple-Class Exposed Relapsed/Refractory Multiple Myeloma (RRMM) Treated with Linvoseltamab in Linker-MM1: Interim Assessment up to 36 Weeks of Treatment

Blood (2023) 142 (Supplement 1): 3359.

https://doi.org/10.1182/blood-2023-179170

Published: 2023

Journal Articles

Unraveling Diverse Mechanisms of Complex Structural Variant Interactions through Multiomic Data in Multiple Myeloma

Enze Liu, Nathan Becker, Parvathi Sudha, Aneta Mikulasova, Mohammad Abu Zaid, Attaya Suvannasankha, Kelvin P. Lee, Rafat Abonour, Brian A. Walker

Blood (2023) 142 (Supplement 1): 641.

https://doi.org/10.1182/blood-2023-186262

Published: 2023

Journal Articles

Prospective Molecular Characterization of Multiple Myeloma Patient Samples Identifies High-Risk Patients and Informs Treatment Sequences through Resistance Mechanisms to Immunotherapies

Phillip Pham, Parvathi Sudha, Lin Wang, Wen Niu, Cameron Morgan, Cameron Ligocki, Ramzi Al-Azzawi, Reynold Ly, Francesco Vetrini, Magdalena Czader, Marwan Tayeh, Mohammad Abu Zaid, Kelvin P. Lee, Attaya Suvannasankha, Rafat Abonour, Brian A. Walker

Blood (2023) 142 (Supplement 1): 4738.

https://doi.org/10.1182/blood-2023-180116

Published: 2023

Journal Articles

Patterns of Response to 200 Mg Linvoseltamab in Patients with Relapsed/Refractory Multiple Myeloma: Longer Follow-Up of the Linker-MM1 Study

Blood (2023) 142 (Supplement 1): 4746.

https://doi.org/10.1182/blood-2023-177968

Published: 2023

Journal Articles

Teclistamab in Relapsed/Refractory Multiple Myeloma: Real-World Outcomes at a Single Academic Center in the Midwest

Adam Stepanovic, Rafat Abonour, Mohammad Abu Zaid, Sherif Farag, Kelvin P. Lee, Attaya Suvannasankha

Blood (2023) 142 (Supplement 1): 7359.

https://doi.org/10.1182/blood-2023-183085

Published: 2023

Journal Articles

Efficacy and safety of cilta-cel in patients with progressive multiple myeloma after exposure to other BCMA-targeting agents

Blood (2023) 141 (3): 219–230.

https://doi.org/10.1182/blood.2022015526

Published: 2023

Includes: Supplemental data

Journal Articles

Updated Safety and Efficacy of REGN5458, a BCMAxCD3 Bispecific Antibody, Treatment for Relapsed/Refractory Multiple Myeloma: A Phase 1/2 First-in-Human Study

Blood (2022) 140 (Supplement 1): 10140–10141.

https://doi.org/10.1182/blood-2022-159969

Published: 2022

Journal Articles

Fingolimod in Combination with Bortezomib Demonstrates Synergistic Tumor Inhibition and Bone Anabolic Effects in Myeloma Bone Disease

Attaya Suvannasankha, Colin D. Crean, David Halladay, David G. Roodman, John Chirgwin

Blood (2022) 140 (Supplement 1): 7104–7105.

https://doi.org/10.1182/blood-2022-171069

Published: 2022

Journal Articles

The Pre-Existing T Cell Landscape Is Associated with Response to High Dose Melphalan and Autologous Stem Cell Transplant in Multiple Myeloma

Mohammad Issam Abu Zaid, Parvathi Sudha, Travis S Johnson, Vivek S. Chopra, Cedric E. Dos Santos, Michael Nixon, Attaya Suvannasankha, Sherif S Farag, Kelvin P. Lee, Rafat Abonour, Brian A. Walker

Blood (2022) 140 (Supplement 1): 9919–9920.

https://doi.org/10.1182/blood-2022-167619

Published: 2022

Journal Articles

Single-Agent Belantamab Mafodotin in Patients with Relapsed or Refractory Multiple Myeloma: Final Analysis of the DREAMM-2 Trial

Blood (2022) 140 (Supplement 1): 7301–7303.

https://doi.org/10.1182/blood-2022-164877

Published: 2022

Journal Articles

The Patient Experience with Belantamab Mafodotin: Perspectives of Patients Receiving Treatment in Clinical Trials and in the Real-World

Blood (2022) 140 (Supplement 1): 13264–13266.

https://doi.org/10.1182/blood-2022-159637

Published: 2022

Journal Articles

Efficacy and Safety of Cilta-Cel in Patients with Progressive Multiple Myeloma after Exposure to Non-Cellular Anti-BCMA Immunotherapy

Blood (2022) 140 (Supplement 1): 4646–4648.

https://doi.org/10.1182/blood-2022-158563

Published: 2022

Journal Articles

Patient Derived Xenografts Highlight Mouse-Specific Tumor Evolution Patterns and Genomic Diversity of Multiple Myeloma

Nathan Becker, Enze Liu, Parvathi Sudha, Aneta Mikulasova, Travis S Johnson, Attaya Suvannasankha, Mohammad Issam Abu Zaid, Rafat Abonour, Brian A. Walker

Blood (2022) 140 (Supplement 1): 9970–9971.

https://doi.org/10.1182/blood-2022-157086

Published: 2022

Journal Articles

Pre-Transplant M Protein Level Predicts Minimal Residual Disease Status after Autologous Stem Cell Transplantation in Multiple Myeloma

Zachary S Meyer, Mohamed Manaa, Yan Han, Magdalena Czader, Attaya Suvannasankha, Rafat Abonour, Sherif S Farag, Melissa Stanley, Mohammad Issam Abu Zaid

Blood (2021) 138 (Supplement 1): 4903.

https://doi.org/10.1182/blood-2021-149595

Published: 2021

Journal Articles

PTHrP May Contribute to Cachexia Accompanying Multiple Myeloma Bone Disease

Attaya Suvannasankha, MD, Colin Crean, BS, Isaac Carrera Ochoa, G David Roodman, MD PhD, John Chirgwin, PhD

Blood (2018) 132 (Supplement 1): 4450.

https://doi.org/10.1182/blood-2018-99-115680

Published: 2018

NARROW

Novel PD-L1 Blocking Peptide with Mitochondrial Targeting Sequence: A Strategy to Counteract Resistance in T-Cell Immunotherapy for Myeloma

Safety and Efficacy of Teclistamab in a Patient Series with Relapsed/Refractory Multiple Myeloma and Severe Renal Impairment on Dialysis

A Timelapse Assessment of Education on Heavily Pretreated Multiple Myeloma: Clinician Perceptions and Patient Experiences

Linvoseltamab in Patients with Relapsed/Refractory Multiple Myeloma: Longer Follow-up and Selected High-Risk Subgroup Analyses of the Linker-MM1 Study

Characterization of Anthropometric Changes in Patients with Relapsed/Refractory Myeloma Treated with BCMA Bispecific Antibody Teclistamab

Health-Related Quality of Life (HRQoL) Among Patients with Triple-Class Exposed Relapsed/Refractory Multiple Myeloma (RRMM) Treated with Linvoseltamab in Linker-MM1: Interim Assessment up to 36 Weeks of Treatment

Unraveling Diverse Mechanisms of Complex Structural Variant Interactions through Multiomic Data in Multiple Myeloma

Prospective Molecular Characterization of Multiple Myeloma Patient Samples Identifies High-Risk Patients and Informs Treatment Sequences through Resistance Mechanisms to Immunotherapies

Patterns of Response to 200 Mg Linvoseltamab in Patients with Relapsed/Refractory Multiple Myeloma: Longer Follow-Up of the Linker-MM1 Study

Teclistamab in Relapsed/Refractory Multiple Myeloma: Real-World Outcomes at a Single Academic Center in the Midwest

Efficacy and safety of cilta-cel in patients with progressive multiple myeloma after exposure to other BCMA-targeting agents

Updated Safety and Efficacy of REGN5458, a BCMAxCD3 Bispecific Antibody, Treatment for Relapsed/Refractory Multiple Myeloma: A Phase 1/2 First-in-Human Study

Fingolimod in Combination with Bortezomib Demonstrates Synergistic Tumor Inhibition and Bone Anabolic Effects in Myeloma Bone Disease

The Pre-Existing T Cell Landscape Is Associated with Response to High Dose Melphalan and Autologous Stem Cell Transplant in Multiple Myeloma

Single-Agent Belantamab Mafodotin in Patients with Relapsed or Refractory Multiple Myeloma: Final Analysis of the DREAMM-2 Trial

The Patient Experience with Belantamab Mafodotin: Perspectives of Patients Receiving Treatment in Clinical Trials and in the Real-World

Efficacy and Safety of Cilta-Cel in Patients with Progressive Multiple Myeloma after Exposure to Non-Cellular Anti-BCMA Immunotherapy

Patient Derived Xenografts Highlight Mouse-Specific Tumor Evolution Patterns and Genomic Diversity of Multiple Myeloma

Pre-Transplant M Protein Level Predicts Minimal Residual Disease Status after Autologous Stem Cell Transplantation in Multiple Myeloma

PTHrP May Contribute to Cachexia Accompanying Multiple Myeloma Bone Disease

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only